A Drug-Drug Interaction (DDI) Study of HDM1002 With Rifampicin and Itraconazole in Healthy Subjects

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 16, 2024

Primary Completion Date

November 19, 2024

Study Completion Date

December 30, 2024

Conditions

Healthy Adult Subject

Interventions

DRUG

HDM1002 and rifampicin

Administered orally

DRUG

HDM1002 and itraconazole

Administered orally

Trial Locations (1)

The second hospital of anhui medical university, Hefei

All Listed Sponsors

lead

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

INDUSTRY

NCT06562088 - A Drug-Drug Interaction (DDI) Study of HDM1002 With Rifampicin and Itraconazole in Healthy Subjects | Biotech Hunter | Biotech Hunter